Sigma Planning Corp Buys New Position in Shire PLC (SHPG)
Sigma Planning Corp bought a new position in Shire PLC (NASDAQ:SHPG) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 1,399 shares of the biopharmaceutical company’s stock, valued at approximately $258,000.
Other institutional investors have also modified their holdings of the company. UBS Group AG increased its position in shares of Shire PLC by 1,825.2% in the first quarter. UBS Group AG now owns 1,227,631 shares of the biopharmaceutical company’s stock worth $211,030,000 after buying an additional 1,163,865 shares during the period. Rockefeller Financial Services Inc. increased its position in shares of Shire PLC by 142.7% in the second quarter. Rockefeller Financial Services Inc. now owns 615,314 shares of the biopharmaceutical company’s stock worth $113,266,000 after buying an additional 361,743 shares during the period. UBS Asset Management Americas Inc. increased its position in shares of Shire PLC by 796.2% in the first quarter. UBS Asset Management Americas Inc. now owns 290,929 shares of the biopharmaceutical company’s stock worth $50,011,000 after buying an additional 258,466 shares during the period. OLD Mission Capital LLC acquired a new position in shares of Shire PLC during the first quarter worth about $28,179,000. Finally, Norges Bank acquired a new position in shares of Shire PLC during the fourth quarter worth about $31,671,000. 24.61% of the stock is owned by institutional investors and hedge funds.
Shire PLC (NASDAQ:SHPG) traded up 2.09% on Friday, reaching $200.60. The company’s stock had a trading volume of 2,264,693 shares. Shire PLC has a 1-year low of $147.60 and a 1-year high of $231.32. The stock has a 50 day moving average price of $195.09 and a 200-day moving average price of $182.40. The company has a market capitalization of $59.75 billion, a price-to-earnings ratio of 41.69 and a beta of 1.11.
Shire PLC (NASDAQ:SHPG) last posted its quarterly earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $3.38 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $3.03 by $0.35. The company had revenue of $2.43 million for the quarter, compared to analysts’ expectations of $2.28 billion. Shire PLC had a return on equity of 17.70% and a net margin of 13.19%. The firm’s revenue was up 55.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.63 earnings per share. Equities analysts predict that Shire PLC will post $12.93 earnings per share for the current fiscal year.
The company also recently disclosed a dividend, which will be paid on Friday, October 7th. Shareholders of record on Friday, September 9th will be given a dividend of $0.139 per share. The ex-dividend date of this dividend is Wednesday, September 7th. Shire PLC’s payout ratio is 15.63%.
SHPG has been the subject of a number of analyst reports. Goldman Sachs Group Inc. reissued a “buy” rating on shares of Shire PLC in a research note on Tuesday, June 28th. Jefferies Group restated a “buy” rating and issued a $262.00 price target on shares of Shire PLC in a report on Wednesday, September 7th. TheStreet cut Shire PLC to a “hold” rating in a report on Thursday, August 4th. Citigroup Inc. restated a “buy” rating on shares of Shire PLC in a report on Friday, July 15th. Finally, Leerink Swann restated a “buy” rating and issued a $213.00 price target (down previously from $225.00) on shares of Shire PLC in a report on Thursday, June 16th. Four equities research analysts have rated the stock with a hold rating and twenty-four have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $230.67.
Shire PLC Company Profile
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.